close
MENU
Investment
3 mins to read

Bogoievski and K1W1 help local biotech firm address US Covid surveillance market

Parnell-based company seek global manufacturing expansion of its antibody tests.

Dita De Boni Thu, 14 Apr 2022

An investment led by former Morrison & Co chief executive Marko Bogoievski and Sir Stephen Tindall’s investment arm K1W1 into local biotech firm Pictor will see the Kiwis partner with a US laboratory to use its test that allows people to see what kind of antibodies they have in the fight against

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Contact the Writer: dita@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Bogoievski and K1W1 help local biotech firm address US Covid surveillance market
Investment,
91229
true